Combining new drugs with chemotherapy for relapsed or refractory acute myeloid leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase I trial evaluates the safety and effectiveness of palbociclib or tazemetostat in combination with CPX-351 for patients with relapsed or refractory acute myeloid leukemia (AML). The study aims to determine the maximum tolerated doses of these enzyme inhibitors alongside standard chemotherapy. Participants will receive either tazemetostat or palbociclib before the chemotherapy, with assessments including bone marrow biopsies and blood sample collections. The goal is to enhance cancer cell death through this combination treatment approach.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Provide signed and dated informed consent form
* Willing to comply with all study procedures and be available for the duration of the study
* Male or female \>= 18 years of age
* Histologically confirmed acute myeloid leukemia (non-M3) relapsed from or refractory to at least 1 prior line of therapy. Bone marrow aspirate and biopsy within 28 days of screening is acceptable. If no prior bone marrow biopsy is available, bone marrow biopsy must be performed during screening unless:

  \* If the subject has \>= 20% myeloblasts present in the peripheral blood, a bone marrow biopsy is not necessary to meet this criterion
* Treatment with a prior investigational agent is acceptable so long as it has not been administered within 2 weeks of enrollment and any prior adverse effects have resolved to grade 1 or less with the exception of alopecia
* Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less
* Life expectancy of at least 4 weeks
* Must be able to consume oral medication
* Subjects must have recovered from the toxic effect of any prior therapy to =\< grade 1 (except alopecia)
* Creatine clearance (CrCL) \>= 45
* Total bilirubin \< 2 x upper limit of normal (ULN)
* Female subjects of childbearing age must have a negative pregnancy test

Exclusion Criteria:

* Subjects with acute promyelocytic leukemia
* Subjects receiving any active chemotherapy agents (except hydroxyurea). Intrathecal methotrexate and cytarabine are permissible
* Subjects whose participation would result in a total cumulative dose of daunorubicin greater than 550 mg/m\^2 or greater than 450 mg/m\^2 if they previously received mediastinal radiation
* Subjects with evidence of active central nervous system (CNS) leukemia involvement. Lumbar puncture is not required for enrollment in the absence of neurologic symptoms
* Subjects must not be receiving growth factors (except erythropoietin)
* Subjects with currently active second malignancy with the exception of nonmelanoma skin cancer, carcinoma in situ of the cervix, resected prostate cancer with Gleason score =\< 6
* Subjects with unstable cardiac disease or uncontrolled arrhythmia
* Subjects with other severe concurrent disease which, in the judgement of the investigator, would make the patient inappropriate to receive high-intensity therapy
* Subjects who are pregnant or breastfeeding
* Subjects with known allergic reactions to components of the study product(s)
* Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study

Where it's running

• Thomas Jefferson University Hospital
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Gina Keiffer, MD — Thomas Jefferson University
• Study coordinator: Gina Keiffer, MD
• Email: gina.keiffer@jefferson.edu
• Phone: 215-955-2929

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Total marrow and lymphoid irradiation with fludarabine and melphalan for older adults with refractory/relapsed AML or high-risk MDS undergoing donor stem cell transplant

  This phase 2 trial tests a targeted radiation conditioning (TMLI) with fludarabine and melphalan before a matched donor stem cell transplant in people aged 50 or older with difficult-to-treat AML or high-risk MDS.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT07582172

• LILRA6 CAR-T therapy for relapsed or refractory acute myeloid leukemia.

  This trial will test LILRA6-directed CAR-T cell therapy to see if it helps adults (18–75) whose acute myeloid leukemia has returned or not responded to prior treatments.

  Recruiting Phase 1 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07263906

• MiRisten to treat relapsed or refractory acute myeloid leukemia

  This phase 1 trial tests whether intravenous miRisten, a miR-126 inhibitor, is safe and tolerable and may help adults with relapsed or refractory acute myeloid leukemia.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT07025564

• Cedazuridine/decitabine with filgrastim dose escalation after stem cell transplant for children with high-risk AML

  This phase 1 trial will test whether giving the oral combination cedazuridine/decitabine (ASTX727) together with filgrastim is safe and find the highest tolerable dose for children with high-risk acute myeloid leukemia after allogeneic stem cell transplant.

  Recruiting at 14 sites Phase 1 National Cancer Institute (NCI) · Birmingham, Alabama and 14 other locations · NCT07012044

• Decitabine plus FLAG‑Ida chemotherapy and total‑body irradiation before donor stem cell transplant for adults with high‑risk myeloid cancers

  This test tries whether adding decitabine to FLAG‑Ida chemotherapy and total‑body irradiation before a donor stem cell transplant helps adults with high‑risk or relapsed myeloid blood cancers live longer and stay in remission.

  Recruiting Phase 1/2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT06928662

• CD83-targeted CAR T cell therapy for adults with relapsed or refractory acute myeloid leukemia

  This Phase 1 trial tests a personalized CD83-targeted CAR T-cell infusion to try to eliminate leukemia cells in adults whose AML has relapsed or not responded to prior treatment.

  Recruiting Phase 1 Roswell Park Cancer Institute · Buffalo, New York · NCT06871410

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.